Previous Close | 348.01 |
Open | 346.11 |
Bid | 0.00 x 900 |
Ask | 0.00 x 1000 |
Day's Range | 341.53 - 348.09 |
52 Week Range | 231.87 - 384.44 |
Volume | |
Avg. Volume | 2,830,577 |
Market Cap | 325.056B |
Beta (5Y Monthly) | 0.38 |
PE Ratio (TTM) | 51.44 |
EPS (TTM) | 6.65 |
Earnings Date | Feb 02, 2023 |
Forward Dividend & Yield | 4.52 (1.32%) |
Ex-Dividend Date | Feb 14, 2023 |
1y Target Est | 389.56 |
Subscribe to Yahoo Finance Plus to view Fair Value for LLY
Pharmaceutical giant Eli Lilly is planting the seeds for a long-term commitment in Research Triangle Park.
Eli Lilly and Co said on Friday the U.S. health regulator approved its drug for the treatment of a rare form of blood cancer. The Food and Drug Administration gave accelerated approval to Jaypirca for the treatment of adults mantle cell lymphoma after at least two lines of therapy.
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. Jaypirca was approved under the FDA's Accelerated Approval pathway based on response rate from the open-label, single